Zacks Research Upgrades Carl Zeiss Meditec (OTCMKTS:CZMWY) to Hold

Carl Zeiss Meditec (OTCMKTS:CZMWY) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks reports.

Other analysts also recently issued reports about the company. Morgan Stanley began coverage on Carl Zeiss Meditec in a research report on Wednesday, September 2nd. They set an “underweight” rating for the company. The Goldman Sachs Group cut Carl Zeiss Meditec from a “hold” rating to a “sell” rating in a research report on Monday. Finally, UBS Group cut Carl Zeiss Meditec from a “neutral” rating to a “sell” rating in a research note on Tuesday, August 11th. Two research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Carl Zeiss Meditec has an average rating of “Strong Sell”.

Carl Zeiss Meditec Price Performance

Carl Zeiss Meditec stock opened at $35.60 on Tuesday. Carl Zeiss Meditec has a 52 week low of $26.65 and a 52 week high of $55.94. The company’s 50 day moving average price is $35.74 and its two-hundred day moving average price is $32.46.

Carl Zeiss Meditec Company Profile

Carl Zeiss Meditec AG is a Germany-based medical technology company focused on ophthalmology and microsurgery. The company develops, manufactures and distributes diagnostic and therapeutic systems, surgical equipment, implants and related digital solutions for healthcare professionals.

Its ophthalmic portfolio includes devices for eye examinations and diagnostics, laser systems for refractive and cataract procedures, surgical microscopes, intraocular lenses and other products used in cataract, retinal, glaucoma and corneal treatments.